25-hydroxy-cholest-5-en-3-sulfate choline, formulations thereof and methods for preparing, and uses of same

Abstract

25HC3S choline and crystalline 25HC3S choline are described herein. Pharmaceutical formulations of 25HC3S choline such as with crystalline 25HC3S choline and methods of treating or preventing disease with same such as nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), alcoholic hepatitis, acute kidney injury (AKI), psoriasis, atherosclerosis, hypercholesterolemia, hypertriglyceridemia, alcoholic fatty liver disease (AFLD), alcoholic steatohepatitis (ASH), leptin resistance, leptin deficiency, a diabetes condition, an autoimmune condition, an inflammatory condition, a neurological condition, Epstein Barr virus-related growth, and conditions related to fat accumulation and inflammation are further disclosed herein. Methods for preparing 25HC3S, including crystalline 25HC3S choline, are also provided.

Dependencies are inferred from the claim text.